AGIOS PHARMACEUTICALS, INC. Cash Flow Statement
AGIO / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
AGIOS PHARMACEUTICALS, INC. used $373M in operating cash flow and negative free cash flow of $377M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.83 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$412.8M | $673.7M | -$352.1M | -$231.8M | $1.6B | -$327.4M | -$411.5M | -$346.0M | -$314.7M | -$198.5M | -$39.4M | -$53.5M | -$39.4M | -$20.1M | -$23.7M |
| Depreciation & Amortization | $5.2M | $5.7M | $6.6M | $8.4M | $8.8M | $9.4M | $8.0M | $7.2M | $6.4M | $5.7M | $1.4M | - | - | $1.2M | $801.0K |
| Operating Cash Flow | -$373.0M | -$389.8M | -$296.1M | -$309.5M | -$407.3M | -$290.8M | -$370.6M | -$304.4M | -$285.2M | $38.6M | -$56.4M | -$59.4M | -$56.4M | -$49.5M | -$15.2M |
| Capital Expenditures | $4.3M | $1.7M | $999.0K | $4.9M | $5.7M | $14.1M | $12.0M | $7.0M | $4.6M | $9.9M | $1.3M | $2.2M | $1.3M | $1.5M | $1.9M |
| Free Cash Flow | -$377.3M | -$391.5M | -$297.1M | -$314.4M | -$413.1M | -$304.9M | -$382.6M | -$311.4M | -$289.9M | $28.6M | -$57.7M | -$61.6M | -$57.7M | -$51.0M | -$17.1M |
| Share Buybacks | - | - | $0 | $0 | $802.5M | $0 | $0 | - | - | - | - | - | - | - | - |
| FCF Margin | -698.3% | -1072.7% | -1107.5% | -2207.6% | - | - | -324.5% | -329.9% | -2758.5% | 41.0% | -168.7% | -732.0% | -225.8% | - | -78.4% |